M Stratton-Phelps1, W D Wilson, I A Gardner. 1. Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis 95616, USA.
Abstract
OBJECTIVE: To determine whether foals with pneumonia that were treated with erythromycin, alone or in combination with rifampin or gentamicin, had a higher risk of developing adverse effects, compared with foals treated with trimethoprim-sulfamethoxazole (TMS), penicillin G procaine (PGP), or a combination of TMS and PGP (control foals). DESIGN: Retrospective study. ANIMALS: 143 foals < 240 days old. PROCEDURE: Information on age, sex, breed, primary drug treatment, total days of treatment with the primary drug, and whether the foal developed diarrhea, hyperthermia, or respiratory distress was obtained from the medical records. Relative risk (RR) and attributable risk (AR) were calculated to compare risk of adverse reactions between foals treated with erythromycin and control foals. RESULTS: Only 3 (4.3%) control foals developed diarrhea; none developed hyperthermia or respiratory distress. Foals treated with erythromycin had an 8-fold risk (RR, 8.3) of developing diarrhea, compared with control foals, and increased risks of hyperthermia (AR, 25%) and respiratory distress (AR, 15%). CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that use of erythromycin to treat foals with pneumonia was associated with an increased risk of diarrhea, hyperthermia, and respiratory distress, compared with use of TMS or PGP.
OBJECTIVE: To determine whether foals with pneumonia that were treated with erythromycin, alone or in combination with rifampin or gentamicin, had a higher risk of developing adverse effects, compared with foals treated with trimethoprim-sulfamethoxazole (TMS), penicillin G procaine (PGP), or a combination of TMS and PGP (control foals). DESIGN: Retrospective study. ANIMALS: 143 foals < 240 days old. PROCEDURE: Information on age, sex, breed, primary drug treatment, total days of treatment with the primary drug, and whether the foal developed diarrhea, hyperthermia, or respiratory distress was obtained from the medical records. Relative risk (RR) and attributable risk (AR) were calculated to compare risk of adverse reactions between foals treated with erythromycin and control foals. RESULTS: Only 3 (4.3%) control foals developed diarrhea; none developed hyperthermia or respiratory distress. Foals treated with erythromycin had an 8-fold risk (RR, 8.3) of developing diarrhea, compared with control foals, and increased risks of hyperthermia (AR, 25%) and respiratory distress (AR, 15%). CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that use of erythromycin to treat foals with pneumonia was associated with an increased risk of diarrhea, hyperthermia, and respiratory distress, compared with use of TMS or PGP.
Authors: Rachel S Liepman; Jacob M Swink; Greg G Habing; Prosper N Boyaka; Benjamin Caddey; Marcio Costa; Diego E Gomez; Ramiro E Toribio Journal: Animals (Basel) Date: 2022-04-13 Impact factor: 3.231
Authors: N D Cohen; S Giguère; A J Burton; J N Rocha; L J Berghaus; C N Brake; A I Bordin; M C Coleman Journal: J Vet Intern Med Date: 2015-12-22 Impact factor: 3.333
Authors: R G Madrigal; S D Shaw; L A Witkowski; B E Sisson; G P Blodgett; M K Chaffin; N D Cohen Journal: J Vet Intern Med Date: 2016-01-24 Impact factor: 3.333